Tacalyx

Tacalyx is a Berlin-based biotech company founded in 2019 as a spin-out of the Max-Planck-Institute of Colloids and Interfaces (MPICI) in Potsdam, Germany. The company develops novel anticancer therapeutics targeting Tumor Associated Carbohydrate Antigens (TACAs) — carbohydrate structures highly expressed on tumor cells but not in healthy differentiated tissues. Tacalyx's pipeline includes antibody-drug conjugates (ADCs) and other immunotherapeutics targeting TACAs, with its lead TCX-201 programme advancing toward clinical trials after a €11 million funding round in April 2026. Tacalyx is backed by High-Tech Gründerfonds, Kurma Partners, Boehringer Ingelheim Venture Fund, Creathor Ventures, and Max-Planck-Innovation.